Clinical management of sleep disturbances in Alzheimer's disease: current and emerging strategies

Nature and Science of Sleep
Elena Urrestarazu, Jorge Iriarte

Abstract

Sleep and circadian disorders in Alzheimer's disease (AD) are more frequent than in the general population and appear early in the course of the disease. Quality of sleep and quality of life are parallel in these patients, and such disorders also represent a heavy burden for caregivers. Although alterations in melatonin and hypocretins (orexins) seem to play a key role in the origin of these disturbances, the etiology of these disorders is multifactorial, including many factors such as environment, behavior, treatments, and comorbidities, among others. A comprehensive evaluation of sleep in each patient is essential in the design of the treatment that includes nonpharmacological and pharmacological approaches. One particularly interesting point is the possibility of a role of sleep disorders in the pathogenesis of AD, raising the possibility that treating the sleep disorder may alter the course of the disease. In this review, we present an update on the role of sleep disorders in AD, the bidirectional influence of sleep problems and AD, and treatment options. Behavioral measures, bright light therapy (BLT), melatonin, and other drugs are likely well known and correctly managed by the physicians in charge of these patients. In s...Continue Reading

Citations

Mar 23, 2017·Current Neurology and Neuroscience Reports·Yumna Saeed, Sabra M Abbott
Mar 2, 2016·International Journal of Molecular Sciences·Víctor MicóLidia Daimiel
Aug 31, 2018·Journal of Aging and Health·Shanna L BurkeTamara Cadet
May 8, 2018·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Peng LiKun Hu
Sep 1, 2017·Current Opinion in Psychiatry·Kirsi M KinnunenGill Livingston
Jun 15, 2017·Frontiers in Aging Neuroscience·Suzanne Hood, Shimon Amir
May 2, 2018·Journal of Alzheimer's Disease : JAD·Paola ProserpioLino Nobili
Dec 7, 2018·Alzheimer's & Dementia : Translational Research & Clinical Interventions·S Imindu LiyanageDonald F Weaver
Jun 24, 2018·Medical Sciences : Open Access Journal·Jan HomolakKarlo Toljan
Nov 21, 2019·Journal of Alzheimer's Disease : JAD·Soichiro ShimizuHaruo Hanyu
May 28, 2017·Journal of Alzheimer's Disease : JAD·Pavla CermakovaDorota Religa
Nov 20, 2016·Annual Review of Pharmacology and Toxicology·Paul J ColemanJohn J Renger
Jul 14, 2018·Frontiers in Molecular Neuroscience·Chunmei WangJing Chen
Jan 20, 2021·Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism·Tekla Maria KylkilahtiIben Lundgaard
Nov 17, 2020·Neuropsychiatric Disease and Treatment·Leszek Bidzan, Mariola Bidzan
Mar 2, 2021·Neural Regeneration Research·Huang KuangShu-Long Yang
Apr 20, 2021·Neurochemical Research·Md Sahab UddinGhulam Md Ashraf
Jun 15, 2021·Pharmacological Reports : PR·Karolina MaciejewskaPaweł Szymański
Apr 8, 2020·ACS Pharmacology & Translational Science·Jason M UslanerPaul J Coleman
Sep 28, 2021·Drugs & Aging·Joshua P Roland, Donald L Bliwise
Oct 13, 2021·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Luciana L LouzadaEinstein F Camargos

❮ Previous
Next ❯

Methods Mentioned

BETA
sedation

Related Concepts

Related Feeds

Asprosin

Asprosin is a fasting-induced hormone produced in the white adipose tissue to stimulate the hepatic release of glucose into the bloodstream. Discover the latest research on this protein hormone here.